Ipca Laboratories Limited

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUNPHARMA.NS has a market cap of 4.2T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUNPHARMA.NS trades at ₹1,732.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUNPHARMA.NS's P/E ratio is 38.06. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUNPHARMA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUNPHARMA.BO has a market cap of 4.2T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUNPHARMA.BO trades at ₹1,732.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUNPHARMA.BO's P/E ratio is 38.07. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUNPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while DIVISLAB.BO trades at ₹6,294.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas DIVISLAB.BO's P/E ratio is 67.58. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, IPCALAB.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check DIVISLAB.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while DIVISLAB.NS trades at ₹6,293.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas DIVISLAB.NS's P/E ratio is 67.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, IPCALAB.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check DIVISLAB.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while TORNTPHARM.BO trades at ₹4,311.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas TORNTPHARM.BO's P/E ratio is 68.17. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, IPCALAB.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check TORNTPHARM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while TORNTPHARM.NS trades at ₹4,307.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas TORNTPHARM.NS's P/E ratio is 64.27. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, IPCALAB.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check TORNTPHARM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while DRREDDY.NS trades at ₹1,307.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas DRREDDY.NS's P/E ratio is 19.27. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check DRREDDY.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while DRREDDY.BO trades at ₹1,307.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas DRREDDY.BO's P/E ratio is 19.27. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check DRREDDY.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while LUPIN.BO trades at ₹2,245.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas LUPIN.BO's P/E ratio is 23.79. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LUPIN.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while LUPIN.NS trades at ₹2,241.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas LUPIN.NS's P/E ratio is 22.10. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LUPIN.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ZYDUSLIFE.NS has a market cap of 913.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ZYDUSLIFE.NS trades at ₹907.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ZYDUSLIFE.NS's P/E ratio is 18.50. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ZYDUSLIFE.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ZYDUSLIFE.BO has a market cap of 913.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ZYDUSLIFE.BO trades at ₹907.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ZYDUSLIFE.BO's P/E ratio is 18.50. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ZYDUSLIFE.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, MANKIND.NS has a market cap of 844.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while MANKIND.NS trades at ₹2,046.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas MANKIND.NS's P/E ratio is 47.46. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check MANKIND.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, MANKIND.BO has a market cap of 844.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while MANKIND.BO trades at ₹2,046.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas MANKIND.BO's P/E ratio is 47.39. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check MANKIND.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AUROPHARMA.NS has a market cap of 668.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AUROPHARMA.NS trades at ₹1,150.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AUROPHARMA.NS's P/E ratio is 19.17. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AUROPHARMA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AUROPHARMA.BO has a market cap of 667.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AUROPHARMA.BO trades at ₹1,150.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AUROPHARMA.BO's P/E ratio is 19.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AUROPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ALKEM.BO has a market cap of 656.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ALKEM.BO trades at ₹5,492.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ALKEM.BO's P/E ratio is 27.69. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALKEM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ALKEM.NS has a market cap of 656.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ALKEM.NS trades at ₹5,490.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ALKEM.NS's P/E ratio is 28.13. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALKEM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GLENMARK.NS has a market cap of 575.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GLENMARK.NS trades at ₹2,039.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GLENMARK.NS's P/E ratio is 53.95. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLENMARK.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GLENMARK.BO has a market cap of 575.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GLENMARK.BO trades at ₹2,038.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GLENMARK.BO's P/E ratio is 53.90. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLENMARK.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, LAURUSLABS.NS has a market cap of 549.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while LAURUSLABS.NS trades at ₹1,017.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas LAURUSLABS.NS's P/E ratio is 65.24. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LAURUSLABS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, LAURUSLABS.BO has a market cap of 549B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while LAURUSLABS.BO trades at ₹1,017.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas LAURUSLABS.BO's P/E ratio is 65.19. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LAURUSLABS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVENPHAR.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVENPHAR.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, IPCALAB.NS has a market cap of 373.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while IPCALAB.NS trades at ₹1,473.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas IPCALAB.NS's P/E ratio is 41.15. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check IPCALAB.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AJANTPHARM.NS has a market cap of 372.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AJANTPHARM.NS trades at ₹2,978.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AJANTPHARM.NS's P/E ratio is 36.73. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AJANTPHARM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AJANTPHARM.BO has a market cap of 372B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AJANTPHARM.BO trades at ₹2,977.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AJANTPHARM.BO's P/E ratio is 36.71. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AJANTPHARM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, JBCHEPHARM.BO has a market cap of 328.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while JBCHEPHARM.BO trades at ₹2,047.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas JBCHEPHARM.BO's P/E ratio is 43.16. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, IPCALAB.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check JBCHEPHARM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, JBCHEPHARM.NS has a market cap of 328.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while JBCHEPHARM.NS trades at ₹2,046.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas JBCHEPHARM.NS's P/E ratio is 43.17. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, IPCALAB.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check JBCHEPHARM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, EMCURE.NS has a market cap of 272.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while EMCURE.NS trades at ₹1,435.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas EMCURE.NS's P/E ratio is 31.30. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check EMCURE.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PEL.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ASTRAZEN.BO has a market cap of 221.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ASTRAZEN.BO trades at ₹8,871.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ASTRAZEN.BO's P/E ratio is 110.72. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ASTRAZEN.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, WOCKPHARMA.NS has a market cap of 221.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while WOCKPHARMA.NS trades at ₹1,364.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas WOCKPHARMA.NS's P/E ratio is 1100.73. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check WOCKPHARMA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ASTRAZEN.NS has a market cap of 221.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ASTRAZEN.NS trades at ₹8,868.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ASTRAZEN.NS's P/E ratio is 110.84. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ASTRAZEN.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, WOCKPHARMA.BO has a market cap of 221.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while WOCKPHARMA.BO trades at ₹1,364.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas WOCKPHARMA.BO's P/E ratio is 1100.28. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check WOCKPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, PPLPHARMA.BO has a market cap of 214.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while PPLPHARMA.BO trades at ₹162.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas PPLPHARMA.BO's P/E ratio is -132.95. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, IPCALAB.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check PPLPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ERIS.NS has a market cap of 184.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ERIS.NS trades at ₹1,352.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ERIS.NS's P/E ratio is 42.87. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ERIS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ERIS.BO has a market cap of 184.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ERIS.BO trades at ₹1,351.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ERIS.BO's P/E ratio is 42.89. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ERIS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, NEULANDLAB.BO has a market cap of 175.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while NEULANDLAB.BO trades at ₹13,652.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas NEULANDLAB.BO's P/E ratio is 98.08. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NEULANDLAB.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, NEULANDLAB.NS has a market cap of 175.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while NEULANDLAB.NS trades at ₹13,651.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas NEULANDLAB.NS's P/E ratio is 98.19. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NEULANDLAB.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, NATCOPHARM.BO has a market cap of 160B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while NATCOPHARM.BO trades at ₹893.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas NATCOPHARM.BO's P/E ratio is 10.40. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check NATCOPHARM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, NATCOPHARM.NS has a market cap of 159.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while NATCOPHARM.NS trades at ₹893.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas NATCOPHARM.NS's P/E ratio is 10.27. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check NATCOPHARM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, APLLTD.BO has a market cap of 151.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while APLLTD.BO trades at ₹770.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas APLLTD.BO's P/E ratio is 24.06. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check APLLTD.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, APLLTD.NS has a market cap of 151.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while APLLTD.NS trades at ₹769.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas APLLTD.NS's P/E ratio is 24.00. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check APLLTD.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GRANULES.NS has a market cap of 145.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GRANULES.NS trades at ₹599.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GRANULES.NS's P/E ratio is 26.68. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GRANULES.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GRANULES.BO has a market cap of 145.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GRANULES.BO trades at ₹598.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GRANULES.BO's P/E ratio is 26.62. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GRANULES.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, JUBLPHARMA.NS has a market cap of 142.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while JUBLPHARMA.NS trades at ₹901.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas JUBLPHARMA.NS's P/E ratio is 33.10. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, IPCALAB.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check JUBLPHARMA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, JUBLPHARMA.BO has a market cap of 142.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while JUBLPHARMA.BO trades at ₹900.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas JUBLPHARMA.BO's P/E ratio is 33.03. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, IPCALAB.BO is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check JUBLPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, CAPLIPOINT.BO has a market cap of 131.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while CAPLIPOINT.BO trades at ₹1,732.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas CAPLIPOINT.BO's P/E ratio is 21.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to CAPLIPOINT.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPLIPOINT.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, CAPLIPOINT.NS has a market cap of 131.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while CAPLIPOINT.NS trades at ₹1,729.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas CAPLIPOINT.NS's P/E ratio is 21.47. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPLIPOINT.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, COHANCE.BO has a market cap of 120.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while COHANCE.BO trades at ₹314.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas COHANCE.BO's P/E ratio is 62.01. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check COHANCE.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, COHANCE.NS has a market cap of 120.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while COHANCE.NS trades at ₹314.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas COHANCE.NS's P/E ratio is 61.95. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check COHANCE.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ALIVUS.BO has a market cap of 111.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ALIVUS.BO trades at ₹906.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ALIVUS.BO's P/E ratio is 20.52. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALIVUS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ALIVUS.NS has a market cap of 110.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ALIVUS.NS trades at ₹903.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ALIVUS.NS's P/E ratio is 20.41. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALIVUS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPPL.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, VIYASH.NS has a market cap of 95.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while VIYASH.NS trades at ₹219.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas VIYASH.NS's P/E ratio is 84.95. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check VIYASH.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, PGHL.NS has a market cap of 84.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while PGHL.NS trades at ₹5,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas PGHL.NS's P/E ratio is 35.62. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, IPCALAB.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check PGHL.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, PGHL.BO has a market cap of 84.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while PGHL.BO trades at ₹5,069.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas PGHL.BO's P/E ratio is 35.58. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, IPCALAB.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check PGHL.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, STAR.NS has a market cap of 80.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while STAR.NS trades at ₹874.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas STAR.NS's P/E ratio is 15.76. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check STAR.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, STAR.BO has a market cap of 80.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while STAR.BO trades at ₹874.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas STAR.BO's P/E ratio is 15.76. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check STAR.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AKUMS.NS has a market cap of 72.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AKUMS.NS trades at ₹474.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AKUMS.NS's P/E ratio is 22.70. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AKUMS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SHILPAMED.NS has a market cap of 63.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SHILPAMED.NS trades at ₹326.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SHILPAMED.NS's P/E ratio is 28.92. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SHILPAMED.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AARTIPHARM.BO has a market cap of 62.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AARTIPHARM.BO trades at ₹687.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AARTIPHARM.BO's P/E ratio is 29.21. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIPHARM.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AARTIPHARM.NS has a market cap of 62.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AARTIPHARM.NS trades at ₹686.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AARTIPHARM.NS's P/E ratio is 29.17. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIPHARM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, FDC.NS has a market cap of 60.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while FDC.NS trades at ₹374.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas FDC.NS's P/E ratio is 28.09. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check FDC.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, FDC.BO has a market cap of 60.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while FDC.BO trades at ₹370.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas FDC.BO's P/E ratio is 27.84. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check FDC.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SEQUENT.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SEQUENT.BO trades at ₹215.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SEQUENT.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SPARC.NS has a market cap of 41.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SPARC.NS trades at ₹128.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SPARC.NS's P/E ratio is -15.54. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SPARC.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SPARC.BO has a market cap of 41.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SPARC.BO trades at ₹127.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SPARC.BO's P/E ratio is -15.47. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SPARC.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, INNOVACAP.NS has a market cap of 39.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while INNOVACAP.NS trades at ₹683.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas INNOVACAP.NS's P/E ratio is 29.60. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, IPCALAB.BO is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check INNOVACAP.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GUJTHEM.NS has a market cap of 36.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GUJTHEM.NS trades at ₹333.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GUJTHEM.NS's P/E ratio is 76.07. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUJTHEM.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUVEN.NS has a market cap of 34.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUVEN.NS trades at ₹150.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUVEN.NS's P/E ratio is -12.24. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVEN.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SUVEN.BO has a market cap of 34.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SUVEN.BO trades at ₹150.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SUVEN.BO's P/E ratio is -12.25. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVEN.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AARTIDRUGS.BO has a market cap of 33.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AARTIDRUGS.BO trades at ₹371.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AARTIDRUGS.BO's P/E ratio is 16.82. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIDRUGS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, AARTIDRUGS.NS has a market cap of 33.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while AARTIDRUGS.NS trades at ₹371.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas AARTIDRUGS.NS's P/E ratio is 16.79. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIDRUGS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ORCHPHARMA.NS has a market cap of 33.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ORCHPHARMA.NS trades at ₹665.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ORCHPHARMA.NS's P/E ratio is 177.89. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO and ORCHPHARMA.NS have similar daily volatility (3.36).Check ORCHPHARMA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ORCHPHARMA.BO has a market cap of 33.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ORCHPHARMA.BO trades at ₹665.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ORCHPHARMA.BO's P/E ratio is 177.87. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ORCHPHARMA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SHILPAMED.BO has a market cap of 32B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SHILPAMED.BO trades at ₹327.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SHILPAMED.BO's P/E ratio is 28.99. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SHILPAMED.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, RPGLIFE.NS has a market cap of 31.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while RPGLIFE.NS trades at ₹1,908.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas RPGLIFE.NS's P/E ratio is 15.57. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, IPCALAB.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check RPGLIFE.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, RPGLIFE.BO has a market cap of 31.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while RPGLIFE.BO trades at ₹1,905.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas RPGLIFE.BO's P/E ratio is 15.56. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, IPCALAB.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check RPGLIFE.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GUFICBIO.NS has a market cap of 28.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GUFICBIO.NS trades at ₹283.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GUFICBIO.NS's P/E ratio is 49.91. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUFICBIO.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, GUFICBIO.BO has a market cap of 28.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while GUFICBIO.BO trades at ₹283.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas GUFICBIO.BO's P/E ratio is 49.88. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUFICBIO.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, UNICHEMLAB.NS has a market cap of 25.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while UNICHEMLAB.NS trades at ₹356.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas UNICHEMLAB.NS's P/E ratio is 8.54. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check UNICHEMLAB.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, UNICHEMLAB.BO has a market cap of 25.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while UNICHEMLAB.BO trades at ₹356.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas UNICHEMLAB.BO's P/E ratio is 8.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check UNICHEMLAB.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, HIKAL.BO has a market cap of 25.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while HIKAL.BO trades at ₹203.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas HIKAL.BO's P/E ratio is 254.56. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, IPCALAB.BO is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check HIKAL.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, HIKAL.NS has a market cap of 25.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while HIKAL.NS trades at ₹203.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas HIKAL.NS's P/E ratio is -193.93. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, IPCALAB.BO is more volatile compared to HIKAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check HIKAL.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, MOREPENLAB.BO has a market cap of 24.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while MOREPENLAB.BO trades at ₹45.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas MOREPENLAB.BO's P/E ratio is 25.35. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MOREPENLAB.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, MOREPENLAB.NS has a market cap of 24.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while MOREPENLAB.NS trades at ₹45.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas MOREPENLAB.NS's P/E ratio is 25.73. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MOREPENLAB.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, NOVARTIND.BO has a market cap of 24.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while NOVARTIND.BO trades at ₹1,004.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas NOVARTIND.BO's P/E ratio is 25.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NOVARTIND.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, ALEMBICLTD.NS has a market cap of 24.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while ALEMBICLTD.NS trades at ₹94.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas ALEMBICLTD.NS's P/E ratio is 7.51. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALEMBICLTD.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, BLISSGVS.NS has a market cap of 23.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while BLISSGVS.NS trades at ₹225.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas BLISSGVS.NS's P/E ratio is 22.11. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check BLISSGVS.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, BLISSGVS.BO has a market cap of 23.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while BLISSGVS.BO trades at ₹225.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas BLISSGVS.BO's P/E ratio is 22.10. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check BLISSGVS.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SOLARA.BO has a market cap of 22.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SOLARA.BO trades at ₹472.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SOLARA.BO's P/E ratio is -97.81. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SOLARA.BO's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, SOLARA.NS has a market cap of 22.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while SOLARA.NS trades at ₹472.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas SOLARA.NS's P/E ratio is -97.78. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, IPCALAB.BO is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check SOLARA.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, IOLCP.NS has a market cap of 21.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while IOLCP.NS trades at ₹73.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas IOLCP.NS's P/E ratio is 18.53. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, IPCALAB.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check IOLCP.NS's competition here

IPCALAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPCALAB.BO stands at 374.7B. In comparison, IOLCP.BO has a market cap of 21.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,476.95, while IOLCP.BO trades at ₹73.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPCALAB.BO currently has a P/E ratio of 41.23, whereas IOLCP.BO's P/E ratio is 18.49. In terms of profitability, IPCALAB.BO's ROE is +0.12%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, IPCALAB.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check IOLCP.BO's competition here